Dr. John T. Fowler, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical Branch at Galveston (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 528
Licensed in Texas since 2001, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: University of Texas Medical Branch at Galveston
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
TX license L2891 (first issued 2001; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Carmel East & West Columbus, OH
- Christus Southeast Texas- St Elizabeth Beaumont, TX
- Baptist Beaumont Hospital Beaumont, TX
Medical groups
- Beaumont Internal Medicine and Geriatric Assoc. (18 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 528
- Services billed
- 9,526
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 828 | 448 |
| Blood test, comprehensive group of blood chemicals | 811 | 444 |
| Established patient office or other outpatient visit, 30-39 minutes | 806 | 416 |
| Insertion of needle into vein for collection of blood sample | 784 | 435 |
| Blood test, lipids (cholesterol and triglycerides) | 750 | 433 |
| Blood test, thyroid stimulating hormone (tsh) | 729 | 418 |
| Automated urinalysis test | 668 | 365 |
| Hemoglobin a1c level | 506 | 311 |
| Advance care planning, first 30 minutes | 328 | 328 |
| Creatine kinase (cardiac enzyme) level, total | 307 | 213 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 23 payments worth $525 in total to this clinician.
| Otsuka America Pharmaceutical, Inc. | $107 |
|---|---|
| Insulet Corporation | $99.66 |
| Novartis Pharmaceuticals Corporation | $45.96 |
| Pfizer Inc. | $41.70 |
| AbbVie Inc. | $40.51 |
| Exact Sciences Corporation | $33.97 |
| Novo Nordisk Inc | $23.40 |
| Krystal Biotech Inc | $22.65 |
| Food and Beverage | $525 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $1,195,616 in research payments for these studies, mostly to the institutions running them.
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT06653153 - TRANSFORM
Cleerly, Inc. - A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.